Samira Rastgoo

Samira Rastgoo

Auto-generated profile, based on publicly available information

Samira Rastgoo

Department of Cellular and Molecular Nutrition, Faculty of Nutrition Science and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
SRSamira Rastgoo
Samira Rastgoo
SFSahand Tehrani Fateh
Sahand Tehrani Fateh
MNMahlagha Nikbaf-Shandiz
Mahlagha Nikbaf-Shandiz
NRNiloufar Rasaei
Niloufar Rasaei
YAYasaman Aali
Yasaman Aali
OAOmid Asbaghi
Omid Asbaghi

24 February 2023 in Nutrition Journal
Verified
Journal Article
Open access
PDF file
MZMohammad Zamani
Mohammad Zamani
FRFatemeh Rezaiian
Fatemeh Rezaiian
SSSaeede Saadati
Saeede Saadati
KNKaveh Naseri
Kaveh Naseri
DADamoon Ashtary-Larky
Damoon Ashtary-Larky
OAOmid Asbaghi
Omid Asbaghi
Background: Endothelial dysfunction serves as an early marker for the risk of cardiovascular disease (CVD); therefore, it is an attractive site of therapeutic interventions to reduce the risk of CVD. This study was conducted to investigate the effect of folic acid supplementation on endothelial function markers in randomized controlled trials (RCTs). Methods: PubMed, ISI web of science, and Scopus databases were searched up to July 2022 for detecting eligible studies. A random-effects model was used for meta-analysis, and linear Meta-regression and non-linear dose-response analysis were performed to assess whether the effect of folic acid supplementation was affected by the dose and duration of intervention. Cochrane tools were also used to assess the risk of bias in the included studies. Results: Twenty-one studies, including 2025 participants (1010 cases and 1015 controls), were included in the present meta-analysis. Folic acid supplementation significantly affected the percentage of flow-mediated dilation (FMD%) (WMD: 2.59%; 95% CI: 1.51, 3.67; P < 0.001) and flow-mediated dilation (FMD) (WMD: 24.38 μm; 95% CI: 3.08, 45.68; P = 0.025), but not end-diastolic diameter (EDD) (WMD: 0.21 mm; 95% CI: − 0.09, 0.52; P = 0.176), and intercellular adhesion molecule (ICAM) (WMD: 0.18 ng/ml; 95% CI: − 10.02, 13.81; P = 0.755). Conclusions: These findings suggest that folic acid supplementation may improve endothelial function by increasing FMD and FMD% levels. Trial registration: PROSPERO registration cod: CRD42021289744.

30 September 2023 in Clinical Nutrition ESPEN
Verified
Journal Article
Open access
SASeyed Ali Abbas-Hashemi
Seyed Ali Abbas-Hashemi
DHDorsa Hosseininasab
Dorsa Hosseininasab
SRSamira Rastgoo
Samira Rastgoo
FSFarideh Shiraseb
Farideh Shiraseb
OAOmid Asbaghi
Omid Asbaghi
Hypertension is a serious complication linked to a higher risk for organs. Caffeine is a natural component that affects the cardiovascular system, while the mechanisms of its effects are not fully established. Therefore, we aimed to examine the impact of caffeine supplementation on blood pressure (BP) by conducting a systematic review and dose-response meta-analysis of randomized controlled clinical trials (RCTs). We searched online databases using relevant keywords up to July 2022 to identify RCTs using caffeine on systolic (SBP) and diastolic BP (DBP) in adults. Inclusion criteria were adult participants ≥18 years old for subjects, examining the effect of caffeine supplementation on BP, and RCTs studies. A random-effects model was used to estimate the weighted mean difference (WMD) and 95% confidence (CI). The pooled of 11 effect sizes analysis of 8 studies demonstrated significant increases in SBP (WMD:1.94 mmHg; 95%CI:0.52, 3.35; p = 0.007) and DBP (WMD:1.66 mmHg; 95% CI:0.75, 2.57; p = 0.000) after caffeine supplementation. The subgroup analysis showed that caffeine supplementation more effectively increased SBP and DBP in males than females. Moreover, meta-regression analysis demonstrated a significant relationship between the dose of caffeine intake and changes in SBP (p = 0.000), DBP (p = 0.000), and duration of the trial in SBP (p = 0.005), and DBP (p = 0.001). The non-linear dose-response analysis detected the dosage of supplementation >400 mg/day is effective for increasing DBP (p = 0.034), and the duration of supplementation of more than nine weeks makes increasing in both SBP and DBP. This meta-analysis shows that caffeine supplementation significantly increased SBP and DBP in adults.

10 January 2023 in Frontiers in Nutrition
Verified
Journal Article
Open access
MZMohammad Zamani
Mohammad Zamani
NPNaseh Pahlavani
Naseh Pahlavani
MNMahlagha Nikbaf-Shandiz
Mahlagha Nikbaf-Shandiz
NRNiloufar Rasaei
Niloufar Rasaei
RGRasool Ghaffarian-Ensaf
Rasool Ghaffarian-Ensaf
SRSamira Rastgoo
Samira Rastgoo
Background and aims: Hyperglycemia and insulin resistance are concerns today worldwide. Recently, L-carnitine supplementation has been suggested as an effective adjunctive therapy in glycemic control. Therefore, it seems important to investigate its effect on glycemic markers.Methods: PubMed, Scopus, Web of Science, and the Cochrane databases were searched in October 2022 for prospective studies on the effects of L-carnitine supplementation on glycemic markers. Inclusion criteria included adult participants and taking oral L-carnitine supplements for at least seven days. The pooled weighted mean difference (WMD) was calculated using a random-effects model.Results: We included the 41 randomized controlled trials (RCTs) (n= 2900) with 44 effect sizes in this study. In the pooled analysis; L-carnitine supplementation had a significant effect on fasting blood glucose (FBG) (mg/dl) [WMD = −3.22 mg/dl; 95% CI, −5.21 to −1.23;p= 0.002;I2= 88.6%,p< 0.001], hemoglobin A1c (HbA1c) (%) [WMD = −0.27%; 95% CI, −0.47 to −0.07;p= 0.007;I2= 90.1%,p< 0.001] and homeostasis model assessment-estimate insulin resistance (HOMA-IR) [WMD = −0.73; 95% CI, −1.21 to −0.25;p= 0.003;I2= 98.2%,p< 0.001] in the intervention compared to the control group. L-carnitine supplementation had a reducing effect on baseline FBG ≥100 mg/dl, trial duration ≥12 weeks, intervention dose ≥2 g/day, participants with overweight and obesity (baseline BMI 25–29.9 and >30 kg/m2), and diabetic patients. Also, L-carnitine significantly affected insulin (pmol/l), HOMA-IR (%), and HbA1c (%) in trial duration ≥12 weeks, intervention dose ≥2 g/day, and participants with obesity (baseline BMI >30 kg/m2). It also had a reducing effect on HOMA-IR in diabetic patients, non-diabetic patients, and just diabetic patients for insulin, and HbA1c. There was a significant nonlinear relationship between the duration of intervention and changes in FBG, HbA1c, and HOMA-IR. In addition, there was a significant nonlinear relationship between dose (≥2 g/day) and changes in insulin, as well as a significant linear relationship between the duration (weeks) (coefficients = −16.45,p= 0.004) of intervention and changes in HbA1C.Conclusions: L-carnitine could reduce the levels of FBG, HbA1c, and HOMA-IR.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42022358692.

6 September 2023 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
OAOmid Asbaghi
Omid Asbaghi
GSGhazaleh Shimi
Ghazaleh Shimi
FOFatemeh Hosseini Oskouie
Fatemeh Hosseini Oskouie
KNKaveh Naseri
Kaveh Naseri
Reza BagheriReza Bagheri
Reza Bagheri
AWAlexei Wong
Alexei Wong
Prior meta-analytic investigations over a decade ago rather inconclusively indicated that conjugated linoleic acid (CLA) supplementation could improve anthropometric and body composition indices in the general adult population. More recent investigations have emerged, and an up-to-date systematic review and meta-analysis on this topic must be improved. Therefore, this investigation provides a comprehensive systematic review and meta-analysis of randomized controlled trials (RCTs) on the impact of CLA supplementation on anthropometric and body composition (body mass [BM], boy mass index [BMI], waist circumference [WC], fat mass [FM], body fat percentage [BFP], and fat-free mass [FFM]) markers in adults. Online databases search, including PubMed, Scopus, the Cochrane Library, and Web of Science up to March 2022, were utilized to retrieve RCTs examining the effect of CLA supplementation on anthropometric and body composition markers in adults. Meta-analysis was carried out using a random-effects model. The I2 index was used as an index of statistical heterogeneity of RCTs. Among the initial 8351 studies identified from electronic databases search, 70 RCTs with 96 effect sizes involving 4159 participants were included for data analyses. The results of random-effects modeling demonstrated that CLA supplementation significantly reduced BM (WMD: -0.35, 95% CI: -0.54, -0.15, p<0.001), BMI (WMD: -0.15, 95% CI: -0.24, -0.06, p=0.001), WC (WMD: -0.62, 95% CI: -1.04, -0.20, p=0.004), FM (WMD: -0.44, 95% CI: -0.66, -0.23, p<0.001), BFP (WMD: -0.77 %, 95% CI: -1.09, -0.45, p<0.001), and increased FFM (WMD: 0.27, 95% CI: 0.09, 0.45, p=0.003). The high-quality subgroup showed that CLA supplementation fails to change FM and BFP. However, according to high-quality studies, CLA intake resulted in small but significant increases in FFM and decreases in BM and BMI. This meta-analysis study suggests that CLA supplementation may result in a small but significant improvement in anthropometric and body composition markers in an adult population. However, data from high-quality studies failed to show CLA’s body fat-lowering properties. Moreover, it should be noted that the weight loss properties of CLA were small and may not reach clinical importance.

3 January 2024 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
AMAli Mohammadian
Ali Mohammadian
SFSahand Tehrani Fateh
Sahand Tehrani Fateh
MNMahlagha Nikbaf-Shandiz
Mahlagha Nikbaf-Shandiz
FGFatemeh Gholami
Fatemeh Gholami
NRNiloufar Rasaei
Niloufar Rasaei
OAOmid Asbaghi
Omid Asbaghi